- Report
- March 2025
- 181 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- July 2024
- 136 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- May 2024
- 137 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- September 2021
- 40 Pages
China
From €2472EUR$2,600USD£2,076GBP
- Report
- January 2022
- 130 Pages
Global
From €6607EUR$6,950USD£5,551GBP
- Report
- August 2024
- 80 Pages
Japan
From €3327EUR$3,500USD£2,795GBP
- Report
- October 2022
- 27 Pages
Global
€11645EUR$12,250USD£9,783GBP
- Report
- March 2025
- 50 Pages
Global
From €2519EUR$2,650USD£2,116GBP
- Report
- March 2025
- 50 Pages
Global
From €2519EUR$2,650USD£2,116GBP
Mesalazine is a drug used to treat gastrointestinal diseases such as ulcerative colitis and Crohn's disease. It is a type of aminosalicylate, which works by reducing inflammation in the digestive tract. It is available in both oral and rectal forms, and is often used in combination with other medications. Common side effects include nausea, headache, and abdominal pain.
Mesalazine is a widely used drug in the gastrointestinal market, and is often prescribed as a first-line treatment for inflammatory bowel diseases. It is generally well-tolerated and has a low risk of serious side effects. It is also used to treat other conditions such as pouchitis and microscopic colitis.
The mesalazine market is highly competitive, with many companies offering generic and branded versions of the drug. Some of the major players in the market include Pfizer, GlaxoSmithKline, Merck, AstraZeneca, and Novartis. Show Less Read more